AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$UTHR

Mesa Nilda sold $115K of UTHR

Mesa Nilda sold 228 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $505.87 ($505.79–$505.98, $0.12M total) across 2 trades on 2026-09-14.

Original reporting
SEC EDGAR · Mesa Nilda
Published Sep 15, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
high confidence
Mentioned
$UTHR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The sale is modest and does not suggest a change in company fundamentals.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or clinical trial news not disclosed here.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑14

Background

Form 4 filings disclose insider transactions; investors track them for signals.

Company-level read

Ticker impact

$UTHRNeutralHigh confidence
Context

Director Mesa Nilda sold 228 shares of United Therapeutics for $115,337, reducing her stake to 5,580 shares.

Expected impact

Minimal or no price impact.

Evidence & confidence

The transaction size is modest relative to market cap and typical daily volume.

Market effects

Sector

None; the sale does not affect the biotech/healthcare sector broadly.

Regional

None; limited to United Therapeutics shareholders.

Global

Low; no global market effect.

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor subsequent filings for pattern.

Key entities

  • Company
    United Therapeutics Corp

    US‑listed biotech firm (ticker UTHR).

  • Individual
    Mesa Nilda

    Director of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 8
$UTHRMed

UTHR Maintained by RBC Capital -- Price Target Raised to $708

RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.

gurufocus.com1 min